Anti-CD3e mAbs [Visilizumab (HuM291)](MABL-921)

MABL-921

immunesuppression, therapeutic, FC

Engineer antibody

chimpanzee, Human

Visilizumab (HuM291)

Recombinant Antibody

This antibody recognises the human CD3 epsilon. This antibody also competes with OKT3 (Muromonab) for binding site on the human T cells suggesting that they bind overlapping or closely spaced epitopes.

T-cell surface glycoprotein CD3 epsilon chain; T-cell surface antigen T3/Leu-4 epsilon chain; CD3-ε

P07766

The original antibody was generated by immunizing BALB/c mice with activated human T cells as immunogens.

This antibody is derived from its a murine parent antibody called M291. HuM291 was significantly less mitogenic to T cells in vitro as compared to OKT3 and induced the release of much lower levels of the cytokines tumor necrosis factor-α, interferon-γ, and interleukin-10. HuM291 still retained the ability to modulate the CD3 complex and inhibit the mixed lymphocyte reaction. This antibody competes with OKT3 for binding to human T cells, which was detected using flow cytometry (PMID: 10480417). In vitro studies using chimpanzee peripheral blood mononuclear cells (PBMCs), HuM291 was reported to be less mitogenic than OKT3 and effectively depleted peripheral T cells without eliciting clinical signs of cytokine release syndrome, and recovered T cells were functionally normal (PMID: 10480415). Phase 1 trial of HuM291 in patients receiving renal allografts suggested that it was well tolerated and rapidly depleted circulating T cells in a dose-dependent manner and was associated with only mild to moderate symptoms of cytokine release (PMID: 11152101). Treatment with visilizumab (HuM291) in severe steroid-refractory ulcerative colitis induced symptomatic response and clinical response (PMID: 19714757). The (99m)Tc labeled version of this antibody is also recommended for imaging of human T cells and study of human T- lymphocyte trafficking and lymphocytic infiltration of tissues and organs (PMID: 19759100). This antibody is also reported to have some activity in advanced glucocorticoid-refractory acute graft-versus-host disease (GVHD) (PMID: 11929757).

Cole et al. HuM291, a humanized anti-CD3 antibody, is immunosuppressive to T cells while exhibiting reduced mitogenicity in vitro. Transplantation. (1999); 68(4):563-71.PMID:10480417

Describes the generation, characterization and comparison o f this antibody to another anti-CD3e antibody OKT3.

100 μg Purified antibody.

1 mg/ml.

Protein A affinity purified

PBS with 0.02% Proclin 300.

Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at - 20⁰C.